UBS’s TG Therapeutics TGTX Stock Holding History

UBS’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$5K	Sell	500 -1,600	-76%	-$14.8K	﹤0.01%	9485
2014 Q2	$20K	Buy	2,100 +600	+40%	+$3.84K	﹤0.01%	8091
2014 Q1	$10K	Buy	+1,500	New	+$8.88K	﹤0.01%	8916

Other funds holding TGTX

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's TGTX Position: Q3 2014 in Review

UBS increased its TG Therapeutics (TGTX) stake by 200% in Q3 2014, buying an estimated $55.6K and bringing the position to 9,000 shares worth $96K. The position accounts for ﹤0.01% of the portfolio, ranked #6050.

UBS first reported a position in TGTX in Q3 2013 and has held it in 5 quarters since. 66 funds tracked by Wall St. Rank hold TGTX as of Q3 2014.

UBS held 9,000 shares of TG Therapeutics worth $96K as of Q3 2014.
UBS bought 6,000 TG Therapeutics shares in Q3 2014, an estimated $55.6K.
TG Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6050 holding.
UBS first reported a position in TG Therapeutics in Q3 2013 and has held it in 5 quarters since.
66 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.